Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
121. |
ECCT/09/03/01 | REMoxTB A randomised placebo – controlled double blind trial comparing two treatment shortening regimens with the standard regimen (two months ethambutol, isoniazid, rifampicin and pyrazinamide followed by four months isoniazid and rifampicin) namely 1) two months moxifloxacin, isoniazid, rifampicin and pyrazinamide followed by two months moxifloxacin, isoniazid and rifampicin and 2) two months ethambutol, moxifloxacin, rifampicin and pyrazinamide followed by two months moxifloxacin and rifampicin for the treatment of adults with pulmonary tuberculosis |
Principal Investigator(s) 1. Evans Inyangala Amukoye Site(s) in Kenya Kibera D.O Health Centre |
View |
122. |
ECCT/18/07/06 | Hestia 3 A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease |
Principal Investigator(s) 1. Prof Jessie Nyokabi Githanga 2. Videlis Nduba 3. Janet N Oyieko 4. Bernards Ragama Ogutu Site(s) in Kenya 1. Gertrude’s Children’s Hospital (Nairobi City county) 2. Chandaria Health Center Clinical Research Clinic (Nairobi City county) 3. Kenya Medical Research Institute (KEMRI) Kisumu (Kisumu county) 4. KEMRI Kombewa Clinical Research Centre (Nairobi City county) 5. Kondele Children\'s Hospital (Kisumu county) 6. Strathmore University Medical Centre (Nairobi City county) |
View |
123. |
ECCT/16/07/02 | A Randomized Trial of Inflienza Vaccine to Reduce Adverse Vascular Events A Randomized Trial of Inflienza Vaccine to Reduce Adverse Vascular Events |
Principal Investigator(s) 1. Mark Loeb Site(s) in Kenya The Aga Khan University Hospital |
View |
124. |
ECCT/21/07/06 | GBT132_Inclacumab-Ps 3 Trial A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises. |
Principal Investigator(s) 1. Fredrick Asirwa Chite 2. Videlis N Nduba 3. Bernhards Ragama Ogutu Site(s) in Kenya 1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) 2. KEMRI/CRDR (Nairobi City county) 3. KEMRI Siaya Clinical Research Annex (Siaya county) 4. Strathmore University Medical Centre (Nairobi City county) |
View |
125. |
ECCT/21/12/07 | GBT 132- Inclacumab Phase 3 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises. |
Principal Investigator(s) 1. Bernhards Ragama Ogutu 2. Videlis N Nduba 3. Fredrick Asirwa Chite Site(s) in Kenya 1. Strathmore University Medical Centre (Nairobi City county) 2. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) 3. KEMRI/CRDR (Nairobi City county) 4. KEMRI Siaya Clinical Research Annex (Siaya county) |
View |